Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Roly Gosling, PhD, MS

    TitleAssociate Professor
    SchoolUCSF School of Medicine
    DepartmentEpidemiology & Biostatistics
    Address550 16th Street
    San Francisco CA 94158
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      The malaria elimination initiative is focussed on supporting countries to succeed in elimination of both falciparum and vivax malaria. We have a broad range of activities from desk based research producing advocacy and summary materials to highlight the substantial progress of malaria control and elimination world wide, to field based research exploring active surveillance strategies, efficacy of drug based transmission interventions, costing studies of elimination programs and more qualitative research such as case studies. The program also supports countries by supporting regional networks of countries to eliminate malaria (the Asia Pacific Malaria Elimination Network, APMEN and the Eliminating 8, E8 in southern Africa).

      We do have opportunities to send students to support field research studies.

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Stone W, Bousema T, Jones S, Gesase S, Hashim R, Gosling R, Carneiro I, Chandramohan D, Theander T, Ronca R, Modiano D, Arcà B, Drakeley C. IgG responses to Anopheles gambiae salivary antigen gSG6 detect variation in exposure to malaria vectors and disease risk. PLoS One. 2012; 7(6):e40170.
        View in: PubMed PMC3387013
      2. Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, Ghani A, Drakeley C, Gosling R. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med. 2012 Jan; 9(1):e1001165.
        View in: PubMed PMC3269430
      3. Yangzom T, Gueye CS, Namgay R, Galappaththy GN, Thimasarn K, Gosling R, Murugasampillay S, Dev V. Malaria control in Bhutan: case study of a country embarking on elimination. Malar J. 2012; 11:9.
        View in: PubMed PMC3278342
      4. Kunene S, Phillips AA, Gosling RD, Kandula D, Novotny JM. A national policy for malaria elimination in Swaziland: a first for sub-Saharan Africa. Malar J. 2011; 10:313.
        View in: PubMed PMC3219738
      5. Shekalaghe SA, Drakeley C, van den Bosch S, ter Braak R, van den Bijllaardt W, Mwanziva C, Semvua S, Masokoto A, Mosha F, Teelen K, Hermsen R, Okell L, Gosling R, Sauerwein R, Bousema T. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malar J. 2011; 10:247.
        View in: PubMed PMC3169516
      6. Bousema T, Kreuels B, Gosling R. Adjusting for heterogeneity of malaria transmission in longitudinal studies. J Infect Dis. 2011 Jul 1; 204(1):1-3.
        View in: PubMed PMC3307167
      7. Cairns M, Ghani A, Okell L, Gosling R, Carneiro I, Anto F, Asoala V, Owusu-Agyei S, Greenwood B, Chandramohan D, Milligan P. Modelling the protective efficacy of alternative delivery schedules for intermittent preventive treatment of malaria in infants and children. PLoS One. 2011; 6(4):e18947.
        View in: PubMed PMC3080380
      8. Griffin JT, Cairns M, Ghani AC, Roper C, Schellenberg D, Carneiro I, Newman RD, Grobusch MP, Greenwood B, Chandramohan D, Gosling RD. Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS One. 2010; 5(9):e12618.
        View in: PubMed PMC2935388
      9. Conteh L, Sicuri E, Manzi F, Hutton G, Obonyo B, Tediosi F, Biao P, Masika P, Matovu F, Otieno P, Gosling RD, Hamel M, Odhiambo FO, Grobusch MP, Kremsner PG, Chandramohan D, Aponte JJ, Egan A, Schellenberg D, Macete E, Slutsker L, Newman RD, Alonso P, Menéndez C, Tanner M. The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. PLoS One. 2010; 5(6):e10313.
        View in: PubMed PMC2886103
      10. Bousema T, Drakeley C, Gesase S, Hashim R, Magesa S, Mosha F, Otieno S, Carneiro I, Cox J, Msuya E, Kleinschmidt I, Maxwell C, Greenwood B, Riley E, Sauerwein R, Chandramohan D, Gosling R. Identification of hot spots of malaria transmission for targeted malaria control. J Infect Dis. 2010 Jun 1; 201(11):1764-74.
        View in: PubMed
      11. Gosling RD, Cairns ME, Chico RM, Chandramohan D. Intermittent preventive treatment against malaria: an update. Expert Rev Anti Infect Ther. 2010 May; 8(5):589-606.
        View in: PubMed
      12. Cairns M, Gosling R, Carneiro I, Gesase S, Mosha JF, Hashim R, Kaur H, Lemnge M, Mosha FW, Greenwood B, Chandramohan D. Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants. PLoS One. 2010; 5(3):e9467.
        View in: PubMed PMC2830887
      13. Mosha JF, Conteh L, Tediosi F, Gesase S, Bruce J, Chandramohan D, Gosling R. Cost implications of improving malaria diagnosis: findings from north-eastern Tanzania. PLoS One. 2010; 5(1):e8707.
        View in: PubMed PMC2806838
      14. Yip K, Gosling RD, Jones V, Hosein IK. An unusual case of meningococcal meningitis complicated with subdural empyema in a 3 month old infant: a case report. Cases J. 2009; 2:6335.
        View in: PubMed PMC2827145
      15. Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, Lemnge M, Mosha FW, Greenwood B, Chandramohan D. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 31; 374(9700):1521-32.
        View in: PubMed
      16. Cairns M, Gosling R, Gesase S, Mosha J, Greenwood B, Chandramohan D. Mode of action and choice of antimalarial drugs for intermittent preventive treatment in infants. Trans R Soc Trop Med Hyg. 2009 Dec; 103(12):1199-201.
        View in: PubMed PMC3787296
      17. Gysels M, Pell C, Mathanga DP, Adongo P, Odhiambo F, Gosling R, Akweongo P, Mwangi R, Okello G, Mangesho P, Slutsker L, Kremsner PG, Grobusch MP, Hamel MJ, Newman RD, Pool R. Community response to intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in five African settings. Malar J. 2009; 8:191.
        View in: PubMed PMC2734860
      18. Stewart L, Gosling R, Griffin J, Gesase S, Campo J, Hashim R, Masika P, Mosha J, Bousema T, Shekalaghe S, Cook J, Corran P, Ghani A, Riley EM, Drakeley C. Rapid assessment of malaria transmission using age-specific sero-conversion rates. PLoS One. 2009; 4(6):e6083.
        View in: PubMed PMC2698122
      19. Gosling RD, Chandramohan D. RTS,S/AS01E vaccine against malaria. N Engl J Med. 2009 Mar 19; 360(12):1253; author reply 1253-4.
        View in: PubMed
      20. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, Mosha JF, Joho A, Mandia V, Mrema H, Mapunda E, Savael Z, Lemnge M, Mosha FW, Greenwood B, Roper C, Chandramohan D. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS One. 2009; 4(2):e4569.
        View in: PubMed PMC2644264
      21. Cairns M, Gosling R, Chandramohan D. Placental malaria increases malaria risk in the first 30 months of life: not causal. Clin Infect Dis. 2009 Feb 15; 48(4):497-8; author reply 498-9.
        View in: PubMed
      22. Ghani AC, Sutherland CJ, Riley EM, Drakeley CJ, Griffin JT, Gosling RD, Filipe JA. Loss of population levels of immunity to malaria as a result of exposure-reducing interventions: consequences for interpretation of disease trends. PLoS One. 2009; 4(2):e4383.
        View in: PubMed PMC2634959
      23. Mwanziva C, Shekalaghe S, Ndaro A, Mengerink B, Megiroo S, Mosha F, Sauerwein R, Drakeley C, Gosling R, Bousema T. Overuse of artemisinin-combination therapy in Mto wa Mbu (river of mosquitoes), an area misinterpreted as high endemic for malaria. Malar J. 2008; 7:232.
        View in: PubMed PMC2588630
      24. Gosling RD, Chandramohan D. Tackling malaria today: Beware resurgence of malaria where incidence has fallen. BMJ. 2008; 337:a1592.
        View in: PubMed
      25. Gosling RD, Drakeley CJ, Mwita A, Chandramohan D. Presumptive treatment of fever cases as malaria: help or hindrance for malaria control? Malar J. 2008; 7:132.
        View in: PubMed PMC2488354
      26. Gosling RD. Asymptomatic malaria associated with protection: not causal. Clin Infect Dis. 2008 Jul 1; 47(1):147; author reply 147-8.
        View in: PubMed
      27. Cairns M, Carneiro I, Milligan P, Owusu-Agyei S, Awine T, Gosling R, Greenwood B, Chandramohan D. Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS One. 2008; 3(5):e2227.
        View in: PubMed PMC2375060
      28. Gosling RD, Ghani AC, Deen JL, von Seidlein L, Greenwood BM, Chandramohan D. Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? Malar J. 2008; 7:54.
        View in: PubMed PMC2323384
      29. Gosling RD, Drakeley CJ, Chandramohan D. Effective malaria control: better burden estimates needed. Lancet. 2008 Mar 1; 371(9614):724.
        View in: PubMed
      30. Whitty C, Gosling R. Implications of attempts to eliminate malaria for front-line clinicians. Trop Doct. 2008 Jan; 38(1):1-2.
        View in: PubMed
      31. Grobusch MP, Egan A, Gosling RD, Newman RD. Intermittent preventive therapy for malaria: progress and future directions. Curr Opin Infect Dis. 2007 Dec; 20(6):613-20.
        View in: PubMed
      32. Shekalaghe S, Drakeley C, Gosling R, Ndaro A, van Meegeren M, Enevold A, Alifrangis M, Mosha F, Sauerwein R, Bousema T. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One. 2007; 2(10):e1023.
        View in: PubMed PMC1995753
      33. Masika PM, Semarundu WJ, Urassa R, Mosha J, Chandramohan D, Gosling RD. Over-diagnosis of malaria is not a lost cause. Malar J. 2006; 5:120.
        View in: PubMed PMC1712345
      34. Gosling RD, Schellenberg DM, Chandramohan D. Single-dose sulfadoxine-pyrimethamine in intermittent preventive treatment of malaria. J Infect Dis. 2006 Jun 1; 193(11):1609-10; author reply 1610-1.
        View in: PubMed
      35. Gillespie SH, Gosling RD, Uiso L, Sam NE, Kanduma EG, McHugh TD. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother. 2005 Dec; 56(6):1169-71.
        View in: PubMed
      36. Drakeley C, Gosling R, Reyburn H. Malaria diagnosis and treatment: one size does not fit all. PLoS Med. 2005 Jun; 2(6):e156; author reply e165.
        View in: PubMed PMC1160571
      37. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003 Dec 1; 168(11):1342-5.
        View in: PubMed
      38. Gosling RD, Heifets L, Gillespie SH. A multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugs. J Antimicrob Chemother. 2003 Sep; 52(3):473-6.
        View in: PubMed
      Roly's Networks
      Related Concepts
      Derived automatically from this person's publications.
      Related Authors
      People who share related concepts with this person.
      Back to TOP